Related by context. All words. (Click for frequent words.) 72 antiviral activity 71 favorable pharmacokinetic profile 70 antiviral efficacy 68 oral bioavailability 68 bactericidal activity 67 S/GSK# 67 dose proportionality 66 dose proportional pharmacokinetics 65 viral kinetics 65 potent antitumor activity 65 potent antiviral 64 Interferon alpha 64 inecalcitol 64 pharmacokinetic profiles 64 CCX# 64 preclinical efficacy 64 antitumor efficacy 64 favorable tolerability 64 HCV replicon 64 ANAVEX #-# [001] 64 IFN α 64 demonstrated antitumor activity 64 low dose ritonavir 63 oral prodrug 63 Thiovir 63 vitro potency 63 anticancer activity 63 ENMD # 63 retapamulin 63 pharmacokinetic characteristics 63 tolerability profiles 63 INCB# [001] 63 nanomolar potency 63 elvucitabine 63 pharmacokinetic PK profile 63 XmAb# 63 pharmacokinetic properties 63 riociguat 62 OHR/AVR# 62 biodistribution 62 vivo efficacy 62 milatuzumab 62 radezolid 62 anti EGFR antibody 62 antiangiogenic activity 62 immunomodulation 62 protease inhibitor PI 62 NEUGENE 62 virologic responses 62 immune modulating 62 virologic 62 pharmacokinetic profile 62 virologic suppression 62 pomalidomide 62 antitumor activity 62 tolerability profile 62 hA# 62 vivo potency 62 pharmacodynamic properties 62 caspofungin 62 solithromycin 62 AST ALT 62 pharmacokinetic interactions 62 VIR# 62 liposomal formulation 62 pharmacodynamic PD 62 viral titers 62 pegylated liposomal doxorubicin 61 cytotoxicity 61 linear pharmacokinetics 61 MabCampath 61 immunological responses 61 pegylated interferon alfa 61 davunetide intranasal AL 61 BAL# [002] 61 Preclinical studies 61 posaconazole 61 Pharmacokinetic studies 61 immune reconstitution 61 pharmacodynamic profile 61 Moxifloxacin 61 ADAGIO study 61 oral FTY# 61 Telbivudine 61 xenograft models 61 effector function 61 vitro cytotoxicity 61 neuroprotective properties 61 Traficet EN 61 alpha 2a 61 amprenavir 61 influenza VLP vaccine 61 TMC# r 61 clinically meaningful efficacy 61 nanomolar 61 ORMD 61 potent inhibition 61 vidofludimus 61 TNFa 61 PRTX 61 relapsed MM 61 CIMZIA ™ 61 CTAP# Capsules 61 potency selectivity 61 GLYX 61 Pharmacokinetic 61 Onconase 61 virological response 60 tumorigenicity 60 azacytidine 60 dose ritonavir 60 HQK 60 antitumor 60 atazanavir Reyataz 60 Tarvacin 60 reactogenicity 60 antigenicity 60 trodusquemine 60 Multimeric 60 mapatumumab 60 DXL# 60 pyrazinamide 60 ritonavir boosted lopinavir 60 renal toxicity 60 CD8 responses 60 neutralizing antibody 60 combination antiretroviral therapy 60 indinavir 60 liposomal amphotericin B 60 PROCHYMAL 60 antibody responses 60 ritonavir boosted 60 teriflunomide 60 potent anti angiogenic 60 tipranavir 60 bevirimat 60 transgene expression 60 imatinib therapy 60 delafloxacin 60 iroxanadine 60 Aliskiren 60 Azedra 60 GHRH 60 lenalidomide dexamethasone 60 systemically administered 60 AZT zidovudine Retrovir 60 cMET 60 flavopiridol 60 TG# [003] 60 Privigen 60 GAMMAGARD 60 HBV vaccine 60 NEVO ™ 60 analgesic efficacy 60 Pharmacokinetic parameters 60 gemcitabine Gemzar 60 fosamprenavir 60 busulfan 60 rhIL 7 60 Xanafide 60 antibody titers 60 BAL# [001] 60 CaPre TM 60 anti leukemic 60 nanoviricide drug 60 TRAIL R2 60 pharmacokinetic parameters 59 liposome formulation 59 effector functions 59 ELISPOT 59 cannabinor 59 HBeAg seroconversion 59 mg kg BID 59 MYDICAR ® 59 LT NS# 59 fosbretabulin 59 evaluating tivozanib 59 lymphocyte counts 59 efficacy 59 preclinically 59 Zoraxel 59 lopinavir 59 IV bisphosphonates 59 MET amplification 59 nanoviricides 59 binding affinity 59 micafungin 59 LSI #P 59 bortezomib Velcade 59 CGEN # 59 plasma pharmacokinetics 59 CIMZIA TM 59 UPLYSO 59 neutralizing antibody responses 59 Dasatinib 59 isoproterenol 59 beta lactam antibiotic 59 steroid dexamethasone 59 DACH platinum 59 fluvastatin 59 peripheral blood mononuclear 59 immunogenicity 59 enfuvirtide 59 canakinumab 59 Protelos 59 nanoviricide 59 RAPAFLO R 59 NEUGENE antisense 59 nucleotide analogue 59 CLORETAZINE TM VNP#M 59 fumagillin nanoparticles 59 systemic bioavailability 59 HIV RNA 59 PEG IFN 59 omega interferon 59 ribavirin RBV 59 OncoVEX 59 paricalcitol 59 Belerofon 59 Omacetaxine mepesuccinate 59 CCR9 59 ruxolitinib 59 virological suppression 59 highly immunogenic 59 potent inhibitory 59 Symadex 59 murine mouse 59 immunomodulator 59 vivo validation 59 cefotaxime 59 selective modulator 59 nucleotide analog 59 inhibitor RG# 59 genotypic resistance 59 CANCIDAS 59 immunomodulatory effects 59 APTIVUS 59 Vidofludimus 59 antitumor effects 59 RoACTEMRA 59 K ras mutations 59 Apoptone 59 seroprotection 59 tumor xenografts 59 conventional DMARDs 59 platelet inhibitor 59 Valortim 59 vitro experiments 59 telbivudine 59 OncoVEX GM CSF 59 tipranavir r 59 PRT# 59 ara C 59 pegylated interferons 59 paliperidone ER 59 cytoprotective 59 APTIVUS R 59 antiapoptotic 59 liposomal doxorubicin 59 Nilotinib 59 neuroprotective effects 59 decitabine 59 null responder 59 Durezol 59 nitazoxanide 59 MGd 59 Telintra 59 DOXIL 59 antiangiogenic therapy 59 orally bioavailable 59 REMUNE R 59 abacavir lamivudine 59 NNRTI resistance 59 PEGylated interferon 59 amrubicin 58 humanized antibody 58 pharmacokinetic PK 58 ACZ# 58 intravascular hemolysis 58 Cethromycin 58 adefovir 58 alfa 2a 58 5alpha reductase 58 Androxal TM 58 Archexin 58 rilpivirine 58 NNRTI resistant virus 58 TAKSTA 58 TNF α 58 M#V mutation 58 rilonacept 58 liver histology 58 anti CD3 58 clevidipine 58 HCV protease inhibitors 58 locoregional disease 58 SPIRIVA HandiHaler 58 novel VDA molecule 58 tanespimycin 58 CBLC# 58 antiandrogens 58 genotypic 58 ganetespib 58 DAVANAT 58 L asparaginase 58 antidepressant efficacy 58 bicalutamide 58 amphotericin B 58 lamivudine refractory patients 58 erythropoietic 58 xenografts 58 immunostimulatory 58 Sym# 58 Bezielle 58 therapeutic regimens 58 Significant teratogenic 58 HIF PH inhibitors 58 pharmacokinetics PK 58 INT# [002] 58 Aflibercept 58 darunavir ritonavir 58 antitumor effect 58 FluCide 58 PS# [001] 58 interferon IFN 58 durable remissions 58 imexon 58 OXi# 58 pan HDAC inhibitor 58 EDEMA3 trial 58 virologic response 58 TRIOLEX 58 Ceplene/IL-2 58 deferiprone 58 complete cytogenetic response 58 SERMs 58 HuMax CD# 58 daunorubicin 58 chemotherapeutic drug 58 pharmacodynamic 58 peginterferon alfa 58 nonclinical studies 58 dosage regimens 58 transfection efficiency 58 Elitek 58 APTIVUS r 58 Zysolin TM 58 Valortim R 58 Anticalins ® 58 bendamustine 58 Genz # 58 pimecrolimus 58 nucleoside analog 58 pharmacodynamic effects 58 Natalizumab 58 fluconazole resistant 58 receptor inhibitor 58 agonism 58 SRT# [003] 58 Ophena TM 58 CDK inhibitor 58 maximally tolerated dose 58 elvitegravir 58 PEG Interferon lambda 58 PBMCs 58 temsirolimus Torisel ® 58 ispinesib administered 58 acromegalic patients 58 Darinaparsin 58 bronchodilatory 58 Gilead Viread 58 colon carcinoma 58 Technosphere Insulin 58 IMA# 58 IFN beta 58 immunized mice 58 Aptivus ® 58 tigecycline 58 CCR2 58 Cyclosporine 58 apremilast 58 thrombopoietin 58 tenofovir DF 58 raltegravir 58 Gleevec resistant 58 antiproliferative effects 58 Copegus ribavirin 58 prucalopride 58 serum urate levels 58 Taxotere chemotherapy 58 synthase TS 58 MP4OX 58 transdermal estradiol 58 HCV protease 58 calcineurin inhibitors 58 ACE inhibitor ramipril 58 Radezolid 58 oral JAK1 58 tenofovir emtricitabine 58 investigational protease inhibitor 58 NS#/#A protease 58 immune modulatory 58 NPH insulin 58 IOP lowering 58 Doxil ® 58 EndoTAG TM -1 58 mcg dose 58 VELCADE melphalan 58 PegIFN RBV 58 viral suppression 58 GAP #B# 58 BMS# 58 IFN gamma 58 rHuPH# 57 intravenous cyclophosphamide 57 Vaxfectin 57 CA4P 57 Aeroquin 57 viraemia 57 HBsAg 57 #ME# 57 immunofluorescence staining 57 pharmacokinetic 57 selective agonist 57 subcutaneously administered 57 sitaxsentan 57 serum antibody 57 Amplimexon 57 cetuximab Erbitux ® 57 HGS ETR1 mapatumumab 57 indibulin 57 A3 adenosine receptor 57 peginterferon alpha 2a 57 ProSavin 57 VLP vaccines 57 low dose cytarabine 57 Antiviral Activity 57 hemagglutination inhibition HAI 57 Non inferiority 57 GFT# 57 H#N# VLP vaccine 57 ImmunoVEX HSV2 57 gp# vaccine 57 Raltegravir 57 favorable pharmacokinetic 57 imatinib Gleevec 57 replicon 57 transfected cells 57 adenoviral 57 lenalidomide Revlimid R 57 anti angiogenic agent 57 REP# 57 pegylated IFN 57 murine model 57 KRAS status 57 gemifloxacin 57 BNC# 57 HIF PHI 57 Immunogenicity 57 neointimal proliferation 57 DexaSite 57 PSMA ADC 57 interferon alfa 57 bronchodilation 57 pharmacokinetic equivalence 57 pharmacodynamic endpoints 57 Protelos R 57 Tolerability 57 Tezampanel 57 NRTI resistance 57 sorafenib Nexavar 57 mesalamine granules 57 pegylated alpha interferon 57 EOquin TM 57 Imprime PGG 57 Cipralex ® 57 sCD# 57 LC#m# 57 ceftazidime 57 HBeAg 57 inhaled iloprost 57 HuLuc# 57 olmesartan 57 antibody titer 57 LPA1 receptor 57 antiangiogenic agents 57 Interferon beta 57 inhibited tumor 57 PEG SN# 57 pharmacodynamic profiles 57 erlotinib Tarceva ® 57 TTR gene 57 ARIKACE 57 mycophenolate mofetil 57 mGluR2 NAM 57 TRV# [001] 57 docetaxel Taxotere ® 57 levodopa induced dyskinesia 57 gadobutrol 57 polymerase inhibitor 57 IL 1ß 57 DermaVir Patch 57 iniparib 57 potent antitumor 57 Elacytarabine 57 #HT#A 57 nonnucleoside reverse transcriptase inhibitors 57 R#/MEM # 57 lomitapide 57 chlorambucil 57 AVI NEUGENE 57 adenovirus vectors 57 NNRTIs 57 mycophenolate mofetil MMF 57 anti HBs 57 taxane resistant 57 HGS ETR2 57 gemcitabine Gemzar ® 57 RGB # 57 administered subcutaneously 57 iSONEP 57 Retisert 57 galiximab 57 trastuzumab Herceptin ® 57 ritonavir boosted protease inhibitor 57 rHuEPO 57 nucleotide analogs 57 mecamylamine 57 zoledronate 57 CHO cells 57 GeoVax vaccines 57 MAGE A3 ASCI 57 Carfilzomib 57 peg IFN 57 FOSRENOL ® 57 tumor xenograft models 57 protein kinase inhibitor 57 thalidomide Thalomid 57 IFN γ 57 urocortin 2 57 non nucleoside 57 PREZISTA r 57 Antitumor Activity 57 salmeterol fluticasone 57 parasitemia 57 CINTREDEKIN BESUDOTOX 57 fluoroquinolone antibiotic 57 darunavir r 57 Aptivus 57 bleomycin 57 lipid lowering therapies 57 NXL# 57 serum phosphorus 57 doxorubicin docetaxel 57 pegylated 57 ORENCIA ® 57 attenuated strain 57 paclitaxel Taxol 57 neurotrophic 57 plasma renin activity 57 dosing frequency 57 trabectedin 57 Panzem R 57 CIMZIA TM certolizumab pegol 57 PEGPH# 57 INGN 57 systemic absorption 57 APOPTONE 57 CCR5 antagonist 57 serum HBV DNA 57 μg ml 57 vivo 57 HepaLife PICM 57 CCR5 tropic HIV 57 ZOLINZA 57 selective orally bioavailable 57 boosted protease inhibitor 57 viremia 57 miconazole 57 phosphorylcholine 57 MYCAMINE 57 antifibrotic 57 oral rivaroxaban 57 vitro studies 56 Virulizin ® 56 beta interferons 56 PlGF 56 granulocyte 56 Alequel ™ 56 pegylated interferon alfa 2a 56 tolerability 56 metaglidasen 56 anti proliferative 56 BRAF inhibitor 56 oblimersen 56 mGluR5 NAM 56 lumiliximab 56 combinability 56 dose dependently 56 pharmacodynamic parameters 56 HCV genotypes 56 intranasal formulation 56 tobramycin 56 Peginterferon 56 subcutaneously injected 56 hour bronchodilation 56 neurotoxicity 56 Darusentan 56 Th2 cytokines 56 L PPDS 56 Plicera 56 nephrotoxicity 56 sunitinib Sutent ® 56 REYATAZ R 56 dose cohort 56 receiving immunosuppressive therapy 56 fusidic acid 56 levodopa carbidopa 56 BARACLUDE ® 56 proteasome inhibitor 56 Immunohistochemical analysis 56 Dabigatran etexilate 56 entecavir 56 interferon alfa 2b 56 INC# 56 Aplidin 56 pharmacokinetic PK study 56 Anthim 56 thymalfasin 56 zileuton 56 nelfinavir 56 Lenalidomide 56 VAPRISOL 56 intranasally administered 56 ULORIC 56 plasma concentrations 56 ancrod 56 hemagglutination inhibition 56 azilsartan medoxomil 56 Alphanate R 56 Pemetrexed 56 INVIRASE 56 Seliciclib 56 calcitonin 56 p# activation 56 Valortim ® 56 Vascugel R 56 IFN alpha 56 mutations conferring 56 idarubicin 56 amifostine 56 GAMMAGARD LIQUID 56 trastuzumab Herceptin R 56 HuMax EGFr 56 bovine thrombin 56 nanopharmaceutical 56 hematological parameters 56 azacitidine 56 ISIS # 56 ATL/TV# 56 somatostatin 56 chemosensitivity 56 #mg dose [002] 56 surface antigen HBsAg 56 Pegasys ® 56 sargramostim 56 TPV r 56 radiation sensitizer 56 MVA BN R 56 MAb 56 nanomolar range 56 ELACYT 56 orally dosed 56 immunosuppressive agents 56 TMC# [002] 56 pyridostigmine 56 intratumoral 56 rhGH 56 CD8 + cytotoxic 56 surrogate endpoint 56 Pegylated Interferon 56 GOUT 56 alagebrium 56 OMP #M# 56 rFIXFc 56 efficacy tolerability 56 REMINYL ® 56 novel nucleoside analog 56 Darunavir 56 estramustine 56 adenoviral vectors 56 itraconazole 56 JVRS 56 Gag polymorphisms 56 TRX# 56 TPI ASM8 56 melphalan prednisone 56 E. faecalis 56 Insulin detemir 56 p# Shc 56 convenient dosing regimens 56 CRLX# 56 cefepime 56 PD LID 56 CG# [003] 56 oral levofloxacin 56 nasal spray formulation 56 glucose lowering 56 eosinophil count 56 stavudine d4T 56 log# reduction 56 bexarotene 56 Inosine 56 immunoreactivity 56 BrachySil TM 56 Denufosol 56 Pharmacokinetics PK 56 MetMAb 56 fluoroquinolone resistance 56 Oral NKTR 56 Th1 type 56 Targretin 56 chlamydial 56 AEGR 56 anti fibrotic 56 rhITF 56 dose dexamethasone 56 azoles 56 meropenem 56 inhibitory effects 56 PEGylated Fab fragment 56 QTc prolongation 56 PROSTVAC TM 56 ESBA# 56 GRNCM1 56 IgM antibodies 56 SGS# 56 humoral responses 56 hematological tumors 56 alkylating agent 56 ELISpot 56 enoximone 56 Golimumab 56 JAK inhibitor 56 immunocompetent 56 myopathy rhabdomyolysis 56 immunosuppressive regimens 56 parathyroid hormone PTH 56 BYETTA exenatide injection 56 TNFalpha 56 YONDELIS 56 plasma kallikrein inhibitor 56 LHRH receptors 56 XL# inhibits 56 Peg IFN 56 CYT# 56 radiotherapy RT 56 hepatic fibrosis 56 coadministration 56 HMG CoA reductase inhibitors 56 Anticalin ® 56 HER2/neu 56 ganciclovir 56 human tumor xenografts 56 Phase 1b trial 56 viral antigens 56 Capesaris 56 dose atorvastatin 56 histone deacetylase inhibitor 56 circulating lymphocytes 56 encapsulates siRNAs 56 IRX 2 56 alicaforsen enema 56 weekly subcutaneous injections 56 PDE4 inhibitors 56 Phase 1a clinical 56 K#R [002] 56 immunomodulatory 56 Mesothelin 56 TPMT 56 SCIg 56 small molecule tyrosine 56 CD8 T cell 56 RhuDex ® 56 DepoVax 56 immunomodulatory therapy 56 Lixivaptan 56 viral antigen 56 somatostatin analog 56 interleukin IL -# 56 rBChE 56 paclitaxel Taxol ® 56 HuMax CD4 56 EGFR antibodies 56 antibody titres 56 Delafloxacin 56 pharmacodynamics PD 56 chronic HBV 56 NAbs 56 intranasal delivery 56 Anticalins R 56 PC# cells 56 PEGylated anti 56 potent antiretroviral therapy 56 sipuleucel T 56 dacetuzumab 56 neuroprotectant 56 colesevelam HCl 56 Pegylated 56 octreotide acetate 56 lymphopenia 56 GeoVax vaccine 56 Kahalalide F 56 leflunomide 56 Engerix B 56 JAK2 inhibitors 56 TLR2 56 inhibitory effect 56 intradermal injection 56 myeloablative 56 #beta estradiol 56 receptor blocker 56 docetaxel Taxotere 56 ChronVac C R 56 pramlintide metreleptin combination 56 locomotor activity 56 NEUMUNE 56 dimeglumine 56 lactate dehydrogenase LDH 56 Epanova 56 VP# [004] 56 Vacc 4x 56 Pharmacokinetic PK 56 molecular remissions 56 adriamycin 56 ACTEMRA TM 56 efavirenz Sustiva 56 nucleoside analogues 56 seropositivity 56 PASI scores 56 lopinavir r 56 Prulifloxacin 56 alvespimycin 55 TBC# 55 elacytarabine 55 Bacillus Calmette Guerin BCG 55 ritonavir boosting 55 antitumour 55 divalproex sodium 55 lapatinib Tykerb 55 adipiplon 55 QT QTc 55 Pimavanserin 55 Muraglitazar 55 basal bolus regimen 55 Blinatumomab 55 corrected QT interval 55 Alferon N 55 tumor specific antigen 55 Naive Patients 55 menadione 55 IgG1 antibodies 55 CD#c 55 uric acid lowering 55 azelaic acid 55 NOD SCID mice 55 K#N 55 neutrophil counts 55 Aclidinium 55 huN# DM1 55 HEK# cells 55 tryptase 55 Altastaph 55 MAP# 55 mitochondrial toxicity 55 tolterodine ER 55 Fc receptor 55 orally administered inhibitor 55 tumor regressions 55 LymphoStat B belimumab 55 AZILECT ® 55 EGFr 55 Chemophase 55 ABC/3TC 55 Civacir 55 fulvestrant 55 Pgp 55 Alocrest 55 platelet inhibition 55 potentially hepatotoxic 55 Vaxfectin TM adjuvant 55 torezolid phosphate 55 carcinoembryonic antigen 55 dopamine partial agonist 55 active moiety 55 partial agonist 55 serum phosphate levels 55 MyVax 55 HCV genotype 55 rhEPO 55 showman instincts 55 efavirenz EFV 55 dasatinib Sprycel 55 Campath alemtuzumab 55 SVR# 55 HepG2 cells 55 IFN alpha 2b 55 HE# [002] 55 elotuzumab 55 Tolvaptan 55 unboosted 55 fluticasone salmeterol 55 mAb 55 PXD# 55 peg interferon 55 comparator PI r 55 cellularity 55 antimicrobial efficacy 55 ciclosporin 55 glycosylation profile 55 oral antiviral 55 EGFR expression 55 OMNARIS HFA 55 t# c# CLA 55 standard chemotherapy regimens 55 administered concomitantly 55 transaminase elevations 55 samalizumab 55 TriRima 55 selective inhibition 55 Omacetaxine 55 haematologic 55 eculizumab therapy 55 LEXIVA r 55 transdermal testosterone patch 55 talabostat 55 tipranavir ritonavir 55 ToGA 55 Gefitinib 55 PSN# [002] 55 antiresorptive 55 TLR agonists 55 Locteron 55 virus HCV protease inhibitor 55 preclinical studies 55 VIDAZA ® 55 glycosylated hemoglobin levels 55 EGS# 55 Xelox 55 uricase 55 alveolar epithelial cells 55 echinocandins 55 anti amnesic 55 cardiotoxic 55 pleconaril 55 antiproliferative activity 55 LAB CGRP 55 RLY# 55 TYZEKA 55 CHOP chemotherapy 55 Arikace 55 pioglitazone HCl 55 nalbuphine ER 55 LB# [003] 55 DAS# [001] 55 immunotherapeutic vaccine 55 sustained virologic response 55 anti arrhythmic drug 55 griseofulvin 55 tapentadol ER 55 antimicrobial prophylaxis 55 Xeloda ® 55 muscarinic 55 HGS# 55 Certolizumab pegol 55 annexin V 55 Virologic 55 vapreotide acetate 55 SLx 55 DiLA2 liposomes 55 LymphoStat B TM 55 subunit vaccine 55 personalized immunotherapy 55 mGluR5 antagonist 55 pharmacokinetic studies 55 selective antagonist 55 ZFN modified 55 virologic breakthrough 55 tocilizumab 55 microbiological eradication 55 ALB # 55 M2e 55 docetaxel chemotherapy 55 Bortezomib 55 Eligen R B# 55 INVEGA ® 55 aminotransferases 55 glatiramer 55 TH# [003]